Connect with us

Tools & Platforms

How Malawi is taking AI technology to small-scale farmers who don’t have smartphones

Published

on


MULANJE, Malawi (AP) — Alex Maere survived the destruction of Cyclone Freddy when it tore through southern Malawi in 2023. His farm didn’t.

The 59-year-old saw decades of work disappear with the precious soil that the floods stripped from his small-scale farm in the foothills of Mount Mulanje.

He was used to producing a healthy 850 kilograms (1,870 pounds) of corn each season to support his three daughters and two sons. He salvaged just 8 kilograms (17 pounds) from the wreckage of Freddy.

“This is not a joke,” he said, remembering how his farm in the village of Sazola became a wasteland of sand and rocks.

Freddy jolted Maere into action. He decided he needed to change his age-old tactics if he was to survive.

He is now one of thousands of small-scale farmers in the southern African country using a generative AI chatbot designed by the non-profit Opportunity International for farming advice.

AI suggests potatoes

The Malawi government is backing the project, having seen the agriculture-dependent nation hit recently by a series of cyclones and an El Niño-induced drought. Malawi’s food crisis, which is largely down to the struggles of small-scale farmers, is a central issue for its national elections next week.

More than 80% of Malawi’s population of 21 million rely on agriculture for their livelihoods and the country has one of the highest poverty rates in the world, according to the World Bank.

The AI chatbot suggested Maere grow potatoes last year alongside his staple corn and cassava to adjust to his changed soil. He followed the instructions to the letter, he said, and cultivated half a soccer field’s worth of potatoes and made more than $800 in sales, turning around his and his children’s fortunes.

“I managed to pay for their school fees without worries,” he beamed.

AI, agriculture and Africa

Artificial intelligence has the potential to uplift agriculture in sub-Saharan Africa, where an estimated 33-50 million smallholder farms like Maere’s produce up to 70-80% of the food supply, according to the U.N.’s International Fund for Agricultural Development. Yet productivity in Africa — with the world’s fast-growing population to feed — is lagging behind despite vast tracts of arable land.

As AI’s use surges across the globe, so it is helping African farmers access new information to identify crop diseases, forecast drought, design fertilizers to boost yields, and even locate an affordable tractor. Private investment in agriculture-related tech in sub-Saharan Africa went from $10 million in 2014 to $600 million in 2022, according to the World Bank.



Source link

Tools & Platforms

DeepMind CEO Demis Hassabis: ‘AI could cut drug discovery from years to…’; how it is changing medicine worldwide |

Published

on


Artificial intelligence (AI) is rapidly transforming industries, and the pharmaceutical sector is poised to be one of its most significant beneficiaries, reshaping how drugs are discovered, tested, and brought to market. In a recent Bloomberg Television interview, Demis Hassabis, CEO of DeepMind and Nobel laureate, revealed that AI could dramatically reduce drug discovery timelines, potentially cutting years of labor-intensive research down to mere months. DeepMind’s advanced AI models aim to streamline the identification of promising drug candidates, enhance precision, optimize molecular design, and reduce the high failure rates that have historically plagued pharmaceutical development. This breakthrough promises faster access to innovative treatments, lower development costs, improved patient outcomes, and a transformative new era of medical research powered by sophisticated computational intelligence and predictive modeling.

How AI is changing the drug discovery process: DeepMind CEO reveals

Traditional drug discovery involves painstaking laboratory experiments, lengthy clinical trials, and significant trial-and-error testing, often taking 10–15 years from concept to market. According to Hassabis, AI can radically alter this timeline.“In the next couple of years, I’d like to see that cut down in a matter of months, instead of years,” Demis Hassabis said in an interview with Bloomberg Television. “That’s what I think is possible. Perhaps even faster.”DeepMind’s subsidiary, Isomorphic Labs, leverages AI to model complex biological systems, analyse molecular structures, and predict interactions between drugs and proteins. In the Bloomberg interview, Hassabis highlighted that AI can process enormous datasets far faster than human researchers, enabling the identification of promising drug candidates within weeks instead of years.This accelerated approach could not only save valuable time but also optimize resource allocation, ensuring that researchers focus on molecules with the highest likelihood of success.

How AI predictive models are transforming drug discovery and minimising setbacks

A major challenge in drug discovery is the high failure rate: many compounds that look promising in early tests fail in later stages due to inefficacy or harmful side effects. Hassabis emphasized that AI’s predictive capabilities could reduce these failures significantly.DeepMind’s models simulate protein folding and chemical interactions, allowing scientists to forecast how molecules behave in the body. The AI can also suggest novel molecular structures that traditional methods might overlook, expanding the pool of potential therapeutics. By prioritizing candidates most likely to succeed, AI improves efficiency and reduces costly setbacks in research.

AI’s role in speeding up drug development and expanding access

Hassabis discussed the broader implications of AI-driven drug discovery in the Bloomberg interview. Faster development cycles could allow for quicker responses to pandemics, emerging diseases, and critical health crises. Moreover, AI could facilitate the creation of personalized medicine, tailoring treatments to individual genetic profiles, metabolic rates, and disease characteristics.Beyond speed, AI’s efficiency could lower drug development costs, making treatments more accessible globally. This democratization of medicine could have profound social impacts, particularly for developing nations where access to cutting-edge therapies is limited.

From Alzheimer’s to rare cancers: AI leads the way

While Hassabis did not provide specific drug names in the interview, he emphasized that AI models are already being applied to several disease areas, including neurodegenerative disorders, rare genetic conditions, and chronic illnesses. Early studies suggest that computational predictions could significantly reduce the experimental burden and provide actionable leads for human trials.For instance, modeling protein-drug interactions can identify compounds that might mitigate protein misfolding in diseases such as Alzheimer’s. Similarly, AI-driven analysis of molecular pathways could accelerate treatments for rare cancers where conventional drug development is often economically unviable.

AI-driven drug discovery: Challenges

Despite its promise, AI-driven drug discovery is not without challenges. Hassabis pointed out several critical considerations:

  • Regulatory oversight: AI-generated predictions must undergo rigorous validation to meet global drug approval standards.
  • Ethical concerns: Ensuring AI recommendations are safe and equitable is vital, particularly when designing personalized therapies.
  • Collaboration needs: Successful implementation requires coordination between AI specialists, molecular biologists, pharmacologists, and clinicians.

Addressing these challenges will be crucial to translating AI’s predictive power into real-world therapies.Also Read | Abidur Chowdhury: Meet the designer behind Apple’s ultra-slim iPhone Air and its futuristic technology





Source link

Continue Reading

Tools & Platforms

Apple’s AI and search executive Robby Walker to leave: Report

Published

on


FILE PHOTO: Robby Walker, one of Apple’s most senior AI executives, is leaving the company.
| Photo Credit: AP

Robby Walker, one of Apple’s most senior artificial intelligence executives, is leaving the company, Bloomberg News reported on Friday, citing people with knowledge of the matter.

Walker’s exit comes as Apple’s cautious approach to AI has fueled concerns it is sitting out what could be the industry’s biggest growth wave in decades.

The company was slow to roll out its Apple Intelligence suite, including a ChatGPT integration, while a long-awaited AI upgrade to Siri has been delayed until next year.

Walker has been the senior director of the iPhone maker’s Answers, Information and Knowledge team since April this year. He has been with Apple since 2013, according to his LinkedIn profile.

He is planning to leave Apple next month, the report said. Walker was in charge of Siri until earlier this year, before management of the voice assistant was shifted to software chief Craig Federighi.

Apple did not immediately respond to a Reuters request for comment.

Recently, Apple has seen a slew of its AI executives leave to join Meta Platforms. The list includes Ruoming Pang, Apple’s top executive in charge of AI models, according to a Bloomberg report from July.

Meta has also hired two other Apple AI researchers, Mark Lee and Tom Gunter — who worked closely with Pang — for its Superintelligence Labs team.

Mike Rockwell, vice president in charge of the Vision Products Group, would be in charge of Siri virtual assistant as CEO Tim Cook has lost confidence in AI head John Giannandrea’s ability to execute on product development, Bloomberg had reported in March.

At its annual product launch event last week, Apple introduced an upgraded line of iPhones, alongside a slimmer iPhone Air, and held prices steady amid U.S. President Donald Trump’s tariffs that have hurt the company’s profit.

The event, though, was light on evidence of how Apple — a laggard in the AI race — aimes to close the gap with the likes of Google, which showcased the capabilities of its Gemini AI model in its latest flagship phones.



Source link

Continue Reading

Tools & Platforms

Nano Banana AI: ChatGPT vs Qwen vs Grok vs Gemini; the top alternatives to try in 2025 – The Times of India

Published

on



Nano Banana AI: ChatGPT vs Qwen vs Grok vs Gemini; the top alternatives to try in 2025  The Times of India



Source link

Continue Reading

Trending